A sterilization facility in Augusta, Georgia is scheduled to shut down, affecting more than 200 employees.
The closure has been attributed to a combination of regulatory pressure, litigation exposure, and broader business considerations. While those factors are specific to this site, the underlying drivers are not unique. They reflect a set of conditions that are increasingly shaping how ethylene oxide (EO) sterilization capacity is evaluated and maintained across the US.
Regulatory and Legal Pressure Are Reshaping Operating Conditions
EO remains a critical sterilization modality, particularly for complex and heat-sensitive medical devices. However, the operating environment around EO has shifted materially in recent years.
The U.S. Environmental Protection Agency has introduced more stringent emissions standards, requiring facilities to implement advanced abatement systems, continuous monitoring, and enhanced reporting. These upgrades are technically feasible, but they require meaningful capital investment and ongoing operational overhead.
At the same time, EO has become a focal point for litigation. Its classification as a carcinogen, combined with increased public awareness, has led to a growing number of lawsuits tied to facility emissions. Several cases have resulted in significant settlements, totalling ~$1 billion in aggregate, and in some instances, operators have chosen to exit rather than continue under heightened legal exposure.
Community response has also become a more direct operational factor. Facilities are facing increased scrutiny at the local level, which can influence permitting, expansion, and long-term viability.
Capacity Is Becoming More Concentrated and More Fragile
When a sterilization facility shuts down, demand doesn’t disappear, it shifts to more modern facilities that have already made the necessary investments in emissions control and compliance infrastructure. As a result, capacity is becoming more concentrated among a smaller number of sites.
This has two implications:
First, the barrier to maintaining or expanding EO capacity is rising. New entrants face higher upfront costs and a more complex regulatory pathway.
Second, redundancy within the sterilization network is decreasing. With fewer facilities carrying more volume, the system becomes more sensitive to disruption at any single site.
…and these costs aren’t being absorbed by the EO sterilizer. They’re moving downstream, with some manufacturers we’ve spoken to already experiencing double-digit EO sterilization price increases.
Demand Remains Stable, But Supply Conditions Are Changing
Despite these pressures, EO continues to play an essential role in the sterilization of medical devices. For many product categories, it remains the only practical option given material compatibility and packaging constraints.
Demand for EO sterilization remains steady, but the conditions required to supply that capacity are becoming more complex and, in some cases, less attractive for operators.
This is not a short-term imbalance. It is a function of regulatory, legal, and economic factors that are unlikely to reverse in the near term.
Manufacturers Are Reframing How They Evaluate Sterilization Strategy
Historically, selection of a sterilization modality has been driven by technical feasibility, cost, and turnaround time. Those factors remain important, but there’s a growing emphasis on:
- Supply chain resilience, including access to multiple facilities or modalities
- Regulatory and legal exposure, particularly in relation to EO-dependent processes
- Long-term availability of capacity, not just current pricing or scheduling
More organizations are evaluating whether portions of their portfolio can transition to alternative modalities such as accelerator-based sterilization (Electron Beam or X-ray), VHP, and/or Chlorine Dioxide.
A Gradual But Ongoing Transition
The Augusta closure reflects a broader shift in the sterilization industry for both manufacturers and sterilization providers alike. This is not an isolated event, and the litigation risk associated with EO is unfortunately very real.
In Illinois, a landmark verdict resulted in a $363M payment in September 2022. Shortly after, more than 800 claims were resolved in January 2023 through a ~$408 million settlement, followed by additional settlements in 2025. In Georgia, litigation has continued across multiple facilities, including a $20 million plaintiff verdict in 2025 and earlier settlements tied to Sterigenics. In Pennsylvania, B. Braun resolved the majority of claims in 2025 while additional cases remain active. In New Jersey, Cosmed filed for bankruptcy in 2024 amid hundreds of EO-related lawsuits. In California, new litigation was filed in 2024, reinforcing that this is not limited to a single region.
The focus is moving beyond immediate operational considerations toward long-term stability, risk management, and supply chain resilience.
If EO risk, pricing pressure, or capacity constraints are starting to impact your planning, it may be time to evaluate where alternative modalities like E-Beam can help reduce exposure. To learn more about E-Beam, or NextBeam, please send us a message or book a meeting anytime.
Additional Articles We Think You Might Like
Have a question? Speak with a sterilization expert today, at your own convenience.
